Obes Rev 24(7):e13568 Jensen SBK et al (2024) Healthy weight loss maintenance with exercise, GLP-1 receptor agonist, or both combined followed by one year without treatment: a post-treatment analysis of a randomised placebo-controlled trial
If tirzepatide provides meaningful anti-inflammatory benefit, discontinuation could lead to a rebound in inflammatory markers as weight regain occurs and metabolic health deteriorates
Some individuals, particularly those with a history of pancreatitis, medullary thyroid cancer, or severe gastrointestinal issues, may need to consult further with their provider about tirzepatide treatment
This classification allows broader distribution through approved medical suppliers
These secondary measures provide clear evidence that the GLP-1 receptor agonist is having its intended effect on your weight and metabolic health
It is preferred over cyanocobalamin due to its longer duration of action, better retention, and lower toxicity profile